As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives

Core Viewpoint - Aptorum Group Limited announces the addition of Dr. Laura A. Philips to its board of directors following the merger with DiamiR Biosciences Corp, aiming to enhance its strategic initiatives in addressing aging-related diseases [1][3]. Company Overview - Aptorum Group is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic assets for unmet medical needs, particularly in oncology and infectious diseases [8]. - DiamiR Biosciences is a private molecular diagnostics company that develops minimally invasive tests for early detection and monitoring of brain health conditions, utilizing a proprietary platform technology based on microRNA signatures [9]. Leadership Changes - Dr. Laura A. Philips, co-founder and CEO of Spheryx, Inc., joins Aptorum's board as an independent director, bringing extensive experience in life sciences and technology [2][3]. - Following the merger, Dr. Kira Sheinerman from DiamiR will join the combined board, and Dr. Alidad Mireskandari will assume the role of President and COO [4][5]. Strategic Goals - The merger is expected to strengthen market awareness and execution capabilities for both Aptorum and DiamiR, particularly in the development of tests for Alzheimer's and other brain diseases [3][4]. - The transaction is anticipated to close in the fourth quarter of 2025, subject to stockholder approval and customary closing conditions [3].